Sobi's growth is real, and the gout bets will decide how well it carries its debt

The technology

Sobi is a Swedish rare disease company with a commercial portfolio in three areas: haematology, immunology and specialty care. It earned SEK 28,238 million in 2025, so it is a mid-sized seller of existing medicines, not an early-stage biotech. Its largest products by second-quarter sales were Doptelet and Altuvoct, followed by Kineret and Gamifant, with Aspaveli and Tryngolza newer.

The pipeline is also assembled by deal. Pozdeutinurad, an oral URAT1 inhibitor for gout, came with the Arthrosi acquisition in February 2026. NASP pairs nanoencapsulated sirolimus with a uricase enzyme for uncontrolled gout. Lacutamab, an anti-KIR3DL2 antibody, was licensed from Innate Pharma in a deal that became effective on September 16.

The odds

Sobi has two gout programs, one at the FDA and one in Phase 3. NASP received a complete response letter that cited manufacturing and facility deficiencies, with no clinical efficacy or safety concerns identified by the FDA. The BIO, Informa and QLS data for 2011 to 2020 show that 90.6% of NDA or BLA submissions reached approval, which supports the view that manufacturing fixes are usually solvable, though they cost time.

Pozdeutinurad met its primary endpoint in REDUCE 2, with 69.2% of patients on 75 mg below the uric acid target against 8.1% on placebo. REDUCE 1 is still to come. Historically, 57.8% of phase 3 programs reached a filing and 52.4% of drugs entering phase 3 were eventually approved. Tryngolza in severe hypertriglyceridemia has a positive CHMP opinion, with a Commission decision expected in the fourth quarter.

The money

Second-quarter revenue was SEK 7,842 million, up 29% at constant currency, and Sobi raised its 2026 outlook to mid- to high-teens revenue growth with an adjusted EBITA margin in the mid- to high-30s percent. The company had SEK 1,082 million in cash on June 30 and unused committed credit facilities of SEK 9,822 million.

Debt is the constraint. Net debt was SEK 16,126 million, up from SEK 10,081 million at the end of 2025, mainly because of the SEK 8,474 million net cash outlay for Arthrosi. Operating cash flow was SEK 1,912 million in the quarter. Contingent payments for Arthrosi can reach USD 550 million, and the Innate deal adds USD 75 million upfront plus up to USD 505 million in milestones.

The risks

NASP is delayed to a 2027 resubmission, and Sobi has not said how long the manufacturing work will take. Vonjo was written down by SEK 6,612 million in 2025, and Zynlonta by SEK 452 million in the second quarter, so acquired assets have not always held their value.

Leadership is changing. CEO Guido Oelkers will leave by the end of January 2027, and no successor has been named. That coincides with several launches and filings. Altuvoct and Doptelet together made up SEK 3,182 million of second-quarter revenue.

Our read

Sobi is growing quickly and has raised guidance, with sales of existing products behind the numbers. The company used debt to acquire a gout program, and 2027 will test that choice through the pozdeutinurad filing and the NASP resubmission. Leverage limits how much more Sobi can spend on deals, and the Q2 report shows first-half operating cash flow of SEK 3,038 million, lower than the SEK 3,743 million of the first half of 2025 because of inventory build-up. A new chief executive arrives as the pipeline reaches its decision points. Sobi reports third-quarter results on October 27, which should show whether the second-quarter pace held and what management says about the NASP timetable and the leadership search.